## (19) World Intellectual Property Organization International Bureau



550 621

## 1 (1818) 2 (1818) 1 (1818) 2 (181<del>8) 4 (1</del>818) 2 (1818) 2 (1818) 2 (1818) 2 (1818) 2 (1818) 2 (1818) 2 (1818) 2 (1818)

(43) International Publication Date 14 October 2004 (14.10.2004)

(10) International Publication Number

(51) International Patent Classification7:

WO 2004/087668 A1

C07D 215/26

(21) International Application Number:

PCT/EP2004/003479

(22) International Filing Date:

1 April 2004 (01.04.2004)

(25) Filing Language:

**English** 

(26) Publication Language:

English

(30) Priority Data: 60/459,724

2 April 2003 (02.04.2003) US

- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).
- (72) Inventors; and

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

(72) Inventors; and
(75) Inventors/Applicants (for US only): LOHSE, Olivier [FR/FR]; 18, rue des Sapins, F-68170 Rixheim (FR).

PENN, Gerhard [ATVCH]; Im Lohgraben 28, CH-4104
Oberwil (CH). SCHILLING, Hanspeter [CH/CH];
Falkenstrasse 12, CH-4103 Bottmingen (CH).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(75) Title: A PROCESS FOR THE PREPARATION OF 5-(HALOACETYL)-8-(SUBSTITUTED OXY)-(1H)-Quinolin-2-ones involves (i) reacting (a) 8-hydroxy-(IH)-quinolin-2-one with an acylating agent to form 8-acetoxy-(IH)-quinolin-2-one. And the separation of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette. droxy-(1H)-quinolin-2-one; or (b) 8-hydroxy-(lH)-quinolin-2-one with an acylating agent to form 8-acetoxy-(lH)-quinolin-2-one, and treating, in-situ, the 8-acetoxy-(1H)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy-(1H)-quinolin-2-one; or (c) 8-acetoxy-(1H)-quinolin-2-one with a Lewis acid to form 5-acetyl-8-hydroxy-(1H)-quinolin-2-one; (ii) reacting the 5-acetyl-8-hydroxy-(1H)-quinolin-2-one prepared in Step (i) with a compound having the Formula RL in the presence of a base and a solvent to form 5-acetyl-8-substituted oxy-(1H)-quinolin-2-one, wherein R is a protecting group and L is a leaving group; and (iii) reacting the 5-acetyl-8-substituted oxy-(1H)-quinolin-2-one with a halogenating agent in the presence of a solvent to form a 5- $(\alpha$ -haloacetyl)-8-substituted oxy-(1H)-quinolin-2-one.

